Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–311 of 311 matching trials from the live ClinicalTrials.gov search.
Filters: "BTK inhibitor" Clear all
Terminated Phase 2 Interventional Results available

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

NCT02943473
View directory record Official record
Conditions
High Risk Smoldering Multiple Myeloma
Interventions
Ibrutinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 23, 2026, 6:51 PM EDT
Not listed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

NCT05275504
View directory record Official record
Conditions
B-Cell Malignancies
Interventions
TT-01488
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Canton, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 23, 2026, 6:51 PM EDT
Recruiting Phase 2 Interventional

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

NCT07271667
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, B-cell Malignancies
Interventions
Emavusertib, Zanubrutinib
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Miami Beach, Florida • Rochester, Minnesota • Florham Park, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

NCT02514083
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Fludarabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 1Phase 2 Interventional

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT03581942
View directory record Official record
Conditions
Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Interventions
Ibrutinib, Copanlisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

NCT05650723
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Withdrawn Phase 1 Interventional

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

NCT05176691
View directory record Official record
Conditions
CLL/SLL, NHL, MCL, MZL, Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia, Follicular Lymphoma, DLBCL, Richter Syndrome
Interventions
HMPL-760
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
12
States / cities
Anaheim, California • Atlanta, Georgia • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 23, 2026, 6:51 PM EDT
Recruiting Phase 2 Interventional

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

NCT04404088
View directory record Official record
Conditions
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Acalabrutinib, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

NCT04626791
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Bortezomib, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Prednisone, Rituximab, Rituximab and Hyaluronidase Human
Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
New York, New York • Charlotte, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

NCT01974440
View directory record Official record
Conditions
Lymphoma
Interventions
Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
32
States / cities
Gilbert, Arizona • Campbell, California • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 23, 2026, 6:51 PM EDT
Terminated Phase 1 Interventional

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

NCT04477291
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
CG-806
Drug
Lead sponsor
Aptose Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 23, 2026, 6:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Of The Selective PKC-β Inhibitor MS- 553

NCT03492125
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
Interventions
MS-553, acalabrutinib, venetoclax, Rituximab, obinutuzumab
Drug
Lead sponsor
MingSight Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Ann Arbor, Michigan • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 23, 2026, 6:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

Mosunetuzumab for CLL MRD Clearance

NCT07052695
View directory record Official record
Conditions
Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
Interventions
Mosunetuzumab, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib
Drug
Lead sponsor
Inhye Ahn
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 23, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

NCT04450173
View directory record Official record
Conditions
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Venetoclax
Drug · Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

NCT03220022
View directory record Official record
Conditions
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
19
States / cities
La Jolla, California • San Francisco, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

NCT02581930
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

NCT01849263
View directory record Official record
Conditions
Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

NCT01962792
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ibrutinib, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 23, 2026, 6:51 PM EDT
Terminated Phase 1 Interventional

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

NCT02973399
View directory record Official record
Conditions
Cancer
Interventions
SNX-5422 plus ibrutinib
Drug
Lead sponsor
Esanex Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

NCT01236391
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
PCI-32765
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Stanford, California • Hackensack, New Jersey • New Hyde Park, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Results available

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526
View directory record Official record
Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Interventions
Acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 23, 2026, 6:51 PM EDT
Active, not recruiting Phase 3 Interventional

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
864
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 1Phase 2 Interventional

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

NCT02315326
View directory record Official record
Conditions
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Interventions
Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 23, 2026, 6:51 PM EDT